Dr. Daniel Moreira
Claim this profileUniversity of Illinois
Area of expertise
Prostate Cancer
Daniel Moreira has run 4 trials for Prostate Cancer. Some of their research focus areas include:
Prostate Adenocarcinoma
Daniel Moreira has run 2 trials for Prostate Adenocarcinoma.
Affiliated Hospitals
University Of Illinois
University Of Illinois At Chicago
Clinical Trials Daniel Moreira is currently running
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting
2 awards
Phase 3
30 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting
2 awards
Phase 3
More about Daniel Moreira
Clinical Trial Related
7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Daniel Moreira has experience with
- Apalutamide
- Genomic Prostate Score Assay
- Multi-parametric Magnetic Resonance Imaging Study Of The Prostate
- Abiraterone
- Bicalutamide
- Degarelix
Breakdown of trials Daniel Moreira has run
Prostate Cancer
Prostate Adenocarcinoma
Low Testosterone
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Moreira specialize in?
Daniel Moreira focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are Stage II.
Is Daniel Moreira currently recruiting for clinical trials?
Yes, Daniel Moreira is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel Moreira has studied deeply?
Yes, Daniel Moreira has studied treatments such as Apalutamide, Genomic Prostate Score assay, Multi-parametric magnetic resonance imaging study of the prostate.
What is the best way to schedule an appointment with Daniel Moreira?
Apply for one of the trials that Daniel Moreira is conducting.
What is the office address of Daniel Moreira?
The office of Daniel Moreira is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.